Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 18/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30879000 | 1.00 | WDR5 (0.73) | WDR5GAAALDH1A1CYP2D6HTT | |
| SCHEMBL3835859 | 0.90 | MAPT (0.70) | WDR5GAAALDH1A1CYP2D6 | |
| SCHEMBL10126930 | 0.89 | WDR5 (0.61) | WDR5GAAALDH1A1CYP2D6HTT | |
| SCHEMBL30878707 | 0.86 | WDR5 (0.69) | WDR5GAAALDH1A1CYP2D6HTT | |
| SCHEMBL8992892 | 0.86 | ALDH1A1 (0.56) | WDR5GAAALDH1A1CYP2D6 | |
| SCHEMBL10126932 | 0.86 | ALDH1A1 (0.59) | WDR5GAAALDH1A1CYP2D6HTT | |
| SCHEMBL16096147 | 0.85 | WDR5 (0.67) | WDR5GAAALDH1A1CYP2D6HTT | |
| SCHEMBL1970582 | 0.85 | WDR5 (0.67) | WDR5GAAALDH1A1CYP2D6HTT | |
| SCHEMBL15961410 | 0.85 | WDR5 (0.67) | WDR5GAAALDH1A1CYP2D6HTT | |
| SCHEMBL20213949 | 0.84 | WDR5 (1.00) | WDR5GAAALDH1A1CYP2D6HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| WO-2024094963-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-3009428-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-2428508-B9 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-2428508-B1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| CN-102421761-A | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC | 2012-04-18 | — | — | CN | disclosed |
| EP-2428508-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | WDR5 2439/4885GAA 4133/4885ALDH1A1 999/4885 |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | WDR5 1248/4885GAA 3821/4885ALDH1A1 1554/4885 |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | WDR5 1248/4885GAA 3821/4885ALDH1A1 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.